Skip to Content

XOMA Corp XOMA

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics. Its proprietary product candidates are X358, X213, X129, and Gevokizumab. The business operations of the company function through the United States, Europe, and the Asia Pacific. XOMA's primary source of revenue is from license and collaboration arrangements, contract services, and royalties and the majority of the revenue is generated from the United States.

Contact
2200 Powell Street, Suite 310
Emeryville, CA, 94608
T +1 510 204-7200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Slow Growth
Employees 10